CRNX News and Press, Crinetics Pharmaceuticals Inc. From 05/10/24

SAN DIEGO, May 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 176,000 shares of its commo...

2024-05-09 16:16:26 ET More on Crinetics Pharmaceuticals Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade) Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2023 Earnings Call Transcript Crinetics Pharmaceuticals Q1 2024 Earnings Preview ...

Late-Breaking Presentations of Initial Results From Phase 2 Studies of Atumelnant ( CRN 0 4894 ) in Congenital Adrenal Hyperplasia and ACTH-Dependent Cushing’s Syndrome Will be Presented at ENDO June 1-4, 2024 Following Second Positive Phas...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

2024-05-08 17:35:05 ET More on Crinetics Pharmaceuticals Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade) Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2023 Earnings Call Transcript Crinetics, Syndax gain amid pitch at Sohn charity conferen...

Initial Data from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia to be Presented, Along with Initial Findings from Phase 1b/2a ACTH-Dependent Cushing’s Syndrome Trial Data from Phase 3 PATHFNDR 1 and 2 Trials of Paltusotine in Acromegaly will be Presented, in Addit...

SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024, after the close of the U.S. financial markets. Company management will host a conference call at 4:30 p...

Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...

SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 121,300 shares of its c...

2024-04-03 11:37:09 ET More on Crinetics Pharmaceuticals Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade) Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2023 Earnings Call Transcript Crinetics gains as late-stage trial for lead drug succeeds...